Does a large published testing history at FGP imply lot consistency?

The lot number on the vial matches the certificate, which at least rules out the easy problem.

I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious.

My background is quantitative but not chemical, so I can follow an equation more easily than a hand-wave.

Is the standard explanation correct, and if so, what is the evidence for it?

Most suppliers test one vial per lot and report the result as lot homogeneity, which is sampling one item from one lot and extrapolating wildly.

Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.

Stated carefully, if the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

In practice, thermal history during shipping is different for every vial, so a lot that experienced thermal abuse may have internal variation even if it was originally homogeneous.

For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.

The sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

Assume segregation is possible, and design your sampling to catch it if it exists.

edited 23 Jul 2026 by a_lindgren — tightened the wording; no substantive change

Batch testing establishes what can be claimed about the lot as a whole, and the sample size determines how much you can actually claim.

Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.

The ICH Q3A and Q3B thresholds for reporting, identification and qualification of impurities are the framework the pharmaceutical industry works to, and they are worth reading even though nothing in the research-grade supply chain is obliged to meet them, because they tell you which numbers a competent analyst would consider worth reporting at all.

I would treat a "complies with" statement without sampling details as a claim rather than as evidence.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

Start from the question: how many vials from this lot do I need to test to claim that the lot meets specification, and the answer depends on both the lot size and the acceptable risk.

Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.

The relevant pharmacopoeial reference points here are the general chapters on peptide purity and on bacterial endotoxins; both specify method validation requirements that research-grade certificates almost never claim to meet, and the absence of that claim is itself information.

The limitation is that you cannot know for certain without testing every vial, and you almost never can afford to do that.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.